Nature Reviews Cardiology

Article	Citations
COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives	964
Myocardial ischaemia–reperfusion injury and cardioprotection in perspective	620
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions	615
Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension	581
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control	406
Interplay between inflammation and thrombosis in cardiovascular pathology	398
Smart wearable devices in cardiovascular care: where we are and how to move forward	357
Artificial intelligence-enhanced electrocardiography in cardiovascular disease management	355
PPAR control of metabolism and cardiovascular functions	347
Global epidemiology of dyslipidaemias	334
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease	315
Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases	311
Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation	292
Epidemiology of cardiovascular disease in Europe	286
Pathophysiology of sepsis-induced cardiomyopathy	273
Global epidemiology of valvular heart disease	257
Transportation noise pollution and cardiovascular disease	235
Self-powered cardiovascular electronic devices and systems	212
Cellular and molecular pathobiology of heart failure with preserved ejection fraction	208
Epicardial adipose tissue in contemporary cardiology	207
Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6	207
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis	206
Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium	191
Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes	183
Cardiovascular disease in patients with severe mental illness	180

Ceramides and other sphingolipids as drivers of cardiovascular disease	177
The role of cardiac rehabilitation in improving cardiovascular outcomes	173
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms	170
Heart failure with mid-range or mildly reduced ejection fraction	169
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging	154
Systems biology in cardiovascular disease: a multiomics approach	150
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?	146
Optical coherence tomography in coronary atherosclerosis assessment and intervention	146
Lifestyle interventions for the prevention and treatment of hypertension	142
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches	142
Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity	139
Epidemiology of the inherited cardiomyopathies	134
Sit less and move more for cardiovascular health: emerging insights and opportunities	134
The quiescent endothelium: signalling pathways regulating organ-specific endothelial normalcy	124
Integration of novel monitoring devices with machine learning technology for scalable cardiovascular management	124
Genomics of hypertension: the road to precision medicine	112
Transforming growth factor-β in myocardial disease	109
High-density lipoproteins, reverse cholesterol transport and atherogenesis	105
Genomic frontiers in congenital heart disease	104
Blood pressure and its variability: classic and novel measurement techniques	103
Cardiac optogenetics: a decade of enlightenment	101
The role of cellular senescence in cardiac disease: basic biology and clinical relevance	101
Apolipoproteins in vascular biology and atherosclerotic disease	100
Vascular endothelial cell development and diversity	99
Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease	98
Catheter ablation for atrial fibrillation: current indications and evolving technologies	98
Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development	97
Mechanisms and consequences of endothelial cell senescence	96
Applications of artificial intelligence in cardiovascular imaging	89
Cardiovascular risks of climate change	86
Complete versus incomplete coronary revascularization: definitions, assessment and outcomes	84
Climate change and cardiovascular disease: implications for global health	83
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action	82
The role of mitochondrial fission in cardiovascular health and disease	82
Epidemiology and prevention of venous thromboembolism	81
Update on the pathophysiology and medical treatment of peripheral artery disease	80
RNA-targeting and gene editing therapies for transthyretin amyloidosis	80
Cardiac involvement in the long-term implications of COVID-19	79
Sulfide regulation of cardiovascular function in health and disease	77
Obesity and the risk of cardiometabolic diseases	75
Myocardial stunning and hibernation revisited	74
Epidemiology and modifiable risk factors for atrial fibrillation	74
Bleeding avoidance strategies in percutaneous coronary intervention	74
Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology	74
Branched-chain amino acids in cardiovascular disease	73
Clinical utility of polygenic risk scores for coronary artery disease	71
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia	70
Social determinants of atrial fibrillation	70
A fresh look at coronary microembolization	68
Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions	67

Targeted delivery of therapeutic agents to the heart	64
Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs	64
Prevention of atherosclerosis from childhood	62
Immune cell profiling in atherosclerosis: role in research and precision medicine	60
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia	60
Gender medicine: effects of sex and gender on cardiovascular disease manifestation and outcomes	57
Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications	57
Pharmacogenetics to guide cardiovascular drug therapy	57
The evolving cardiac lymphatic vasculature in development, repair and regeneration	55
Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective	54
Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies	54
Targeting the sarcomere in inherited cardiomyopathies	53
The health digital twin: advancing precision cardiovascular medicine	50
Macrophages in cardiac remodelling after myocardial infarction	50
Hallmarks of cardiovascular ageing	49
Electroimmunology and cardiac arrhythmia	49
SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism	49
Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications	47
Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management	46
Obstructive sleep apnoea heterogeneity and cardiovascular disease	46
Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease	45
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing	45
Evolving concepts of the vulnerable atherosclerotic plaque and the vulnerable patient: implications for patient care and future research	44
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention	41
Towards precision medicine in heart failure	41
Sirtuins in atherosclerosis: guardians of healthspan and therapeutic targets	40
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention	39
Increasing representation and diversity in cardiovascular clinical trial populations	38
The contribution of the exposome to the burden of cardiovascular disease	38
The microtubule cytoskeleton in cardiac mechanics and heart failure	38
Remote monitoring and digital health tools in CVD management	37
Stroke prevention strategies in high-risk patients with atrial fibrillation	37
The potential of tailoring the gut microbiome to prevent and treat cardiometabolic disease	37
The COVID-19 pandemic: a catalyst to improve clinical trials	37
Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization	36
Repurposing drugs to treat cardiovascular disease in the era of precision medicine	35
The oral microbiome in the pathophysiology of cardiovascular disease	35
Calcific aortic valve disease: mechanisms, prevention and treatment	35
Flow-induced reprogramming of endothelial cells in atherosclerosis	34
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer	34
Single-cell transcriptomics for the assessment of cardiac disease	34
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential	33
Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities	33
Cardiac fibroblasts and mechanosensation in heart development, health and disease	33
Improving clinical practice guidelines with implementation science	32
Autonomic dysfunction and postural orthostatic tachycardia syndrome in post-acute COVID-19 syndrome	31
Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure	31
Hypertension in China: epidemiology and treatment initiatives	30
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease	30
Temporary mechanical circulatory support devices: practical considerations for all stakeholders	30
Changing epidemiology of congenital heart disease: effect on outcomes and quality of care in adults	29
Interventional therapies for pulmonary embolism	28
Effects of fatty acids on T cell function: role in atherosclerosis	28
The role of aldehyde dehydrogenase 2 in cardiovascular disease	27
A change of heart: new roles for cilia in cardiac development and disease	27
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges	27
The use of new CRISPR tools in cardiovascular research and medicine	25
Pathophysiology and risk factors of peripartum cardiomyopathy	25
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group	25
The need for increased pragmatism in cardiovascular clinical trials	24
Plastics and cardiovascular disease	23
Neuroimmune axis of cardiovascular control: mechanisms and therapeutic implications	22
Genetics and mechanisms of thoracic aortic disease	22
Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization	22
The biology of atherosclerosis comes full circle: lessons for conquering cardiovascular disease	21
Long COVID and cardiovascular disease: a learning health system approach	20
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases	20
Global epidemiology of acute coronary syndromes	19
Diversity 4.0 in the cardiovascular health-care workforce	19
A role for lipophagy in atherosclerosis	18
RNA modifications in cardiovascular health and disease	18
Genomic enhancers in cardiac development and disease	18
Current concepts and novel targets for antiplatelet therapy	18
Clarification of the definition of hypoplastic left heart syndrome	18
Cardiovascular health and disease in migrant populations: a call to action	18
PCSK9-targeted therapies: present and future approaches	17
The bidirectional association between atrial fibrillation and myocardial infarction	17
Trained immunity in atherosclerotic cardiovascular disease	16
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thro	16
Genetics and genomics of arrhythmic risk: current and future strategies to prevent sudden cardiac death	16

Immune and inflammatory mechanisms in hypertension	15
Clonal haematopoiesis and atherosclerosis: a chicken or egg question?	15
Current and future applications of virtual reality technology for cardiac interventions	15
Mechanisms of ryanodine receptor 2 dysfunction in heart failure	14
The ongoing quest for the first total artificial heart as destination therapy	14
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden	14
Nanotherapeutics for cardiovascular disease	13
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease	13
FGF23 and klotho at the intersection of kidney and cardiovascular disease	12
The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis	12
A pathophysiological compass to personalize antianginal drug treatment	12
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries	11
Strategies to prevent burnout in the cardiovascular health-care workforce	11
Travelling with heart failure: risk assessment and practical recommendations	11
A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease	11
The future of cardiac xenotransplantation	11
AIMing 2 treat atherosclerosis	10
Oxidized phospholipids in cardiovascular disease	10
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease	10
Oxidation of miRNAs by ROS leads to cardiac hypertrophy	10
ACE2 level as a marker of CVD	9
Invention and uptake of TAVI over the first 20 years	9
Cardiovascular physiology and pathophysiology at high altitude	9
Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine	9
Cardiovascular health concerns in sexual and gender minority populations	8
Shaping the future of cardiovascular medicine in the new era of wearable devices	8
Role of sex hormones in cardiovascular diseases	8
Heart transplantation: advances in expanding the donor pool and xenotransplantation	8
Macrophages and neutrophils modulate arrhythmia risk after myocardial infarction	7
Uncertainties about left ventricular thrombus after STEMI	7
Guidelines to lower intake of added sugar are necessary and justified	7
Atherosclerotic plaque stabilization and regression: a review of clinical evidence	7
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets	7
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction	7
Cardiac splicing as a diagnostic and therapeutic target	7
Publisher Correction: Cellular and molecular pathobiology of heart failure with preserved ejection fraction	7
Complexity and plasticity of cardiac cellular composition	7
Publisher Correction: Reappraising the role of inflammation in heart failure	6
Animal models to study cardiac regeneration	6
Exosome-derived microRNAs improve cardiac function	6
A roadmap of strategies to support cardiovascular researchers: from policy to practice	6
Collateral cardiovascular damage during the COVID-19 pandemic	6
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction	6
Very high HDL-C levels are associated with higher mortality in patients with CAD	6
Detection of subclinical hypertrophic cardiomyopathy	6
Circadian medicine: a critical strategy for cardiac care	6
Lipoprotein(a), platelet function and cardiovascular disease	6
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale	6
Universal flu vaccines: a shot at lifelong cardioprotection?	6
Empagliflozin improves outcomes in HFrEF regardless of diabetic status	5
Preventing cardiac damage in patients with COVID-19	5
The menopausal transition period and cardiovascular risk	5
A phoenix rises from the ashes of cardiac cell therapy	5
Statins promote efferocytosis in atherosclerotic plaques	5
Effects of lifestyle factors on leukocytes in cardiovascular health and disease	5
Electron microscopy of cardiac 3D nanodynamics: form, function, future	5
Author Correction: Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease	5
The dynamic cardiac cellular landscape: visualization by molecular imaging	5
Piezo1 senses pressure overload and initiates cardiac hypertrophy	5
Human susceptibility to coronary artery disease: lessons from chimpanzee resilience	4
A call for training programmes in cardiovascular genomics	4
Clonal haematopoiesis induces a pro-inflammatory monocyte phenotype in HF	4
Safety of paclitaxel-coated devices in peripheral artery disease	4
Boosting mitochondrial metabolism with dietary supplements in heart failure	4
Publisher Correction: Cardiac involvement in the long-term implications of COVID-19	4
Author Correction: Epidemiology and modifiable risk factors for atrial fibrillation	4
Inflammation in plaque erosion and rupture	4
Machine learning predicts risk in ACS	4
Caffeine consumption and cardiovascular health	4
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course	4
Diversity in human genetics studies accelerates discovery and improves health care	4
Carotid stenosis management: time to address the misconceptions (‘furphies’)	4
Cardiovascular benefits of fermented foods and beverages: still up for debate	4
Exosomes improve myocardial recovery after infarction	4
Immunomodulation and immunopharmacology in heart failure	4
Promising anti-IL-6 therapy for atherosclerosis	4
Defining iron deficiency in patients with heart failure	4
Inclusion of remnant cholesterol improves risk prediction for ischaemic heart disease	4
Targeted therapies for cardiac diseases	3
Limited benefit of triglyceride lowering with fibrates in statin-treated patients	3
Macropinocytosis promotes foam cell formation and atherosclerosis	3
Yoga for the prevention of cardiovascular disease	3
Lovastatin improves endothelial cell function in LMNA-related DCM	3
Macrophages promote endothelial-to-mesenchymal transition after MI	3
Reply to ‘Mechanisms of ryanodine receptor 2 dysfunction in heart failure’	3
Immune checkpoint inhibitors: acute and chronic cardiovascular complications	3
Reduced lymphatic drainage promotes HFpEF and atherosclerosis	3
Are blood-pressure targets needed to prevent cardiovascular disease?	3
ERBB2–YAP crosstalk mediates cardiac regeneration in mice	3
Anti-IL-1β therapy lowers leukocyte supply and uptake in atherosclerosis	3
Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved	3
The need for new clinical trials of old cardiovascular drugs	3
Sotatercept therapy for PAH	3
Hyperglycaemia-induced trained immunity promotes atherosclerosis	3
Modulating the gut microbiota with dietary interventions to protect against cardiometabolic disease	3